Pharnext SA

#Santé & Bien-être #Therapeutics

• Genomics
• Big data
• Artificial intelligence
• Network pharmacology
• Drug repurposing
• Molecule combinations
• Biomarkers

BACKGROUND
Pharnext was founded by renowned scientists and entrepreneurs (including Professor Daniel Cohen, a pioneer in modern genomics) to develop new therapies targeting several key pathological mechanisms in severe orphan and common neurodegenerative diseases.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Pharnext’s approach is applicable to virtually any disorder and particularly suited to multifactorial diseases.
Pharnext is currently focused on neurodegenerative diseases:

• Charcot-Marie-Tooth (CMT1A) disease: PHASE 3 trial completed – with positive topline results.
• Alzheimer’s disease: Phase 2a trial completed.
• ALS: Phase 1 trial completed.

CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
€91 million in equity raised from a foundation.

• Listed on the Euronext Growth trading market in July 2016.
• CMT1A program completed phase 3 trials with positive topline results.

COLLABORATIONS SOUGHT

• Industrial partnerships in the pharmaceutical sector for Pharnext’s candidate drugs.
• R&D collaborations with academic and industrial partners for early programs.

• Further Information

  60 patent families
  45 staff members
  Strengths:
  New paradigm in R&D for faster pharmaceutical developments, particularly in multifactorial diseases. Eminent scientists and breakthrough approaches in pharmacogenomics.
  Innovation assets:
  Innovative drug combinations based on genomic big data and artificial intelligence. Pharnext’s approach can potentially be applied to any disease.